Prestige BioPharma Limited (950210.KS)
KRW 15050.0
(-4.57%)
KRW 15050.0
(-4.57%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -129.76 Billion KRW | -219.24% |
| 2022 | -40.64 Billion KRW | 84.63% |
| 2021 | -264.4 Billion KRW | 41.4% |
| 2020 | -451.2 Billion KRW | -946.93% |
| 2019 | -43.09 Billion KRW | -595.6% |
| 2018 | 8.69 Billion KRW | 182.73% |
| 2017 | 3.07 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | -129.76 Billion KRW | -378.5% |
| 2023 Q1 | -21.22 Billion KRW | 47.79% |
| 2023 Q3 | 46.59 Billion KRW | 109.22% |
| 2023 Q2 | 22.27 Billion KRW | 204.94% |
| 2022 Q1 | -263.28 Billion KRW | 0.42% |
| 2022 Q2 | -200.65 Billion KRW | 23.79% |
| 2022 FY | -40.64 Billion KRW | 84.63% |
| 2022 Q4 | -40.64 Billion KRW | 79.2% |
| 2022 Q3 | -195.38 Billion KRW | 2.63% |
| 2021 Q1 | -442.3 Billion KRW | 1.97% |
| 2021 FY | -264.4 Billion KRW | 41.4% |
| 2021 Q4 | -264.4 Billion KRW | -3.63% |
| 2021 Q3 | -255.14 Billion KRW | 33.24% |
| 2021 Q2 | -382.19 Billion KRW | 13.59% |
| 2020 Q4 | -451.2 Billion KRW | 2.04% |
| 2020 Q3 | -460.57 Billion KRW | 0.0% |
| 2020 FY | -451.2 Billion KRW | -946.93% |
| 2019 FY | -43.09 Billion KRW | -595.6% |
| 2019 Q4 | -43.09 Billion KRW | 0.0% |
| 2018 FY | 8.69 Billion KRW | 182.73% |
| 2017 FY | 3.07 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | -4127.964% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 111.737% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 119.244% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | -1113.181% |
| Green Cross Corporation | 674.31 Billion KRW | 119.244% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | 1712.248% |
| Celltrion, Inc. | 1325.8 Billion KRW | 109.788% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 108.419% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | -21.901% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | -110.488% |